Spravato is only provided after clinical evaluation and safety review. Treatment eligibility depends on diagnosis, prior treatment history, current symptoms, medical and psychiatric safety factors, insurance requirements, and clinical judgment.
What is Spravato?
- For adults with treatment-resistant depression, Spravato may be used alone or together with an oral antidepressant.
- For depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior, Spravato is used together with an oral antidepressant.
- Spravato is administered under direct supervision in a certified treatment setting, and patients are monitored after each treatment.
- Spravato is not taken home.
Important limitation
Spravato has not been demonstrated to prevent suicide or reduce suicidal ideation or behavior, and it does not replace hospitalization when hospitalization is clinically warranted.
Who may qualify?
- Adults with depression who have not had adequate benefit from prior antidepressant trials.
- Eligibility depends on clinical evaluation, diagnosis, medication history, safety factors, and insurance requirements.
- Meadowlark reviews fit carefully before starting treatment.
What treatment day looks like
- Patient arrives for in-office treatment.
- Vitals and safety checks may be completed.
- Medication is administered under supervision as a nasal spray.
- Patient remains in the office for monitoring for at least two hours per REMS requirements.
- Patient cannot drive afterward and must have transportation home.
Safety and rems monitoring
Spravato requires monitoring because it can cause sedation, dissociation, blood pressure changes, dizziness, nausea, and impaired coordination. Patients are monitored after dosing. Treatment is not appropriate for everyone, and safety screening is required.
Insurance and prior authorization
Insurance coverage varies. Prior authorization may be required. Requirements may include diagnosis, prior antidepressant trials, medication history, and clinical documentation. Coverage cannot be guaranteed until eligibility and benefits are reviewed.
How Spravato differs from take-home ketamine
Spravato is FDA-approved esketamine given only in a certified clinic with required post-dose monitoring. It is not the same as compounded take-home ketamine, which has different regulatory status, safety monitoring, and prescribing rules. Meadowlark provides in-office Spravato when clinically appropriate.
Who may not be a good candidate?
- Certain medical risks or unstable blood pressure requiring additional medical clearance
- Active substance misuse concerns
- Certain psychiatric safety risks such as psychosis or mania
- Pregnancy or other clinical factors requiring additional review
Evaluation does not guarantee approval or treatment.
How to start
- New patients can text “register” to 307-300-5885.
- Existing patients can ask their provider whether Spravato evaluation is appropriate.
- Initial evaluation includes depression history, prior medication trials, safety review, and treatment planning.
Spravato safety note
Spravato is only provided after clinical evaluation and safety review. Meadowlark Mind & Body follows applicable Spravato REMS requirements. Patients experiencing suicidal intent, psychosis, mania, severe intoxication, or medical instability may require emergency evaluation, hospitalization, or another higher level of care.